Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Lobel
Rbhs Robert Wood Johnson Medical School, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
BioMarin Pharmaceutical Inc.
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Dr. Lobel receives a portion of license revenues and fees from BioMarin Pharmaceutical. The sponsor of the current study is NIH. This study is closely linked, and basically overlaps with the focus of BioMarin, which is the development of drugs for the treatment of rare diseases. Indeed BioMarin has licensed several of the patents held by Dr. Lobel. The COIC has reviewed this study in the past and since no financial reward was indicated no COI was assigned. However, now a considerable amount of money has been given to Dr. Lobel, his laboratory, the University and to CABM. Although Dr. Lobel states that there is no direct connection between the current study and the earnings disclosed, the relatedness between them is apparent. However since the patents no longer belong to Rutgers and have been sold, royalties from them will also cease to accrue to Dr. Lobel. The Committee, by Rutgers Policy, is concerned only with royalties received during the past 12 months.
Novel Lysosomal Enzyme Deficient in Batten Disease
The proposed research is focused on developing a cure for a fatal hereditary neurodegenerative disease of children, late infantile neuronal ceroid lipofuscinosis (Batten Disease). This research may also be applicable to a number of closely-related diseases and to more widespread human disorders such as Alzheimer disease.
Filed on November 22, 2016.
Tell us what you know about Peter Lobel's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Peter Lobel”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Lobel | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | BioMarin Pharmaceutical Inc. | >$600,000 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.